Send to printer »

GEN News Highlights : Jun 13, 2012

FivePrime Licenses BioWa, Lonza’s Cell Line for Anticancer Antibody Pipeline

Potelligent CHOK1SV generates fucose-free antibodies for increased efficacy and Fc binding.

FivePrime Therapeutics negotiated a license to use BioWa and Lonza’s Potelligent® CHOK1SV cell line as part of the R&D and production of multiple anticancer antibodies in its pipeline. The host cell line combines BioWa’s engineered glycosylation technology Potelligent with Lonza’s GS Gene Expression System, including the CHOK1SV cell line, which is used for the production of therapeutic recombinant proteins and monoclonal antibodies.

“The combination of the clinical validation seen with other Potelligent antibodies and the track record of the GS cell line were key to our decision to select this system to enhance the potential for therapeutic efficacy of our emerging pipeline of antibodies in oncology,” comments Michael Kavanaugh, M.D., svp for research and development at FivePrime.

BioWa and Lonza teamed up to develop the Potelligent CHOK1SV cell line back in 2007, and launched the technology in 2009. BioWa’s Potelligent platform is a method for producing 100% fucose-free monoclonal antibodies in CHO cells, by knocking out the FUT8 gene responsible for the addition of fucose to sugar chains. The technology can be applied to current antibody manufacturing processes. The firm claims knocking out fucose leads to increased Fc receptor binding, results in antibodies that demonstrate a marked increase in antibody-dependent cellular cytotoxicity, and lowers the required therapeutic dose.